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Tuberculosis (TB) and diabetes mellitus (DM) are both important health issues. A bidirectional association between
them has been demonstrated by many researchers. The link of DM and TB is more prominent in developing
countries where TB is endemic and the burden of diabetes mellitus is increasing. The association between diabetes
and tuberculosis may be the next challenge for global tuberculosis control worldwide. Proper planning and
collaboration are necessary to reduce the dual burden of diabetes and TB. One model similar to the TB-HIV program
for prevention, screening and treatment of both diseases can be the best approach. In this paper, we review
existing data and discuss the matters of controversy that would be helpful for determining research priorities
in different countries.
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The first report of the association between DM and TB
was documented by Avicenna (980-1027 AD) over one
thousand years ago. Since that time, the relationship be-
tween diabetes mellitus (DM) and tuberculosis (TB), and
the nature of their interaction with regards to co-
morbidity are largely suggested by numerous epidemio-
logical studies. In the early 20th century, the effect of
DM on TB was large concern of investigators, but this
was somewhat neglected in the second half of the 20th
century with the emergence proper treatment for both
diseases [1,2]. In recent decades, with the increasing
prevalence of TB, particularly Multi Drug Resistant TB
(MDR-TB), and DM cases in the world, the relationship
is re-emerging as a significant public health problem.
The link of DM and TB is more prominent in develop-
ing countries where TB is endemic and the prevalence of
DM is rising.
Although infection with Human Immunodeficiency
Virus (HIV) is considered as the most potent risk factor
for TB, the high prevalence of DM in the world and its
effect on TB burden is greater than HIV infection in* Correspondence: mrmasjedi@gmail.com
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reproduction in any medium, provided the ormany studies [3]. In addition, TB affects DM in many
aspects.
Although the definite pathophysiological mechanism
of the effect of DM as a predisposing risk factor for TB
is unknown, some hypotheses are suggested: depressed
cellular immunity, dysfunction of alveolar macrophages,
low levels of interferon gamma, pulmonary microangi-
opathy, and micronutrient deficiency [4,5].
Few studies in lower income countries have explored
this relationship in light of growing DM prevalence in
the developing world. Furthermore, the focus of most
studies has been to assess the risk of TB in DM patients.
In this paper, we reviewed existing data and discussed
the matters of controversy that will be helpful for deter-
mining priorities of research in different countries.Epidemiology of tuberculosis and diabetes mellitus
The prevalence of TB has been rising in recent years glo-
bally. It is estimated that in 2010 there were 8.8 million
(range: 8.5-9.2 million) new cases of TB. On the other
hand, TB is the cause of death for approximately two mil-
lion people every year [6-8]. The prevalence and incidence
of TB in Iran is estimated to be 23 (8.2-40) and 17 (14-21)
per 100/000 population respectively in 2010 [9].
Aging, changes in life style, socioeconomic factors,
and population growth have lead to an increased preva-
lence of DM, particularly, type 2 DM. The total numberl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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285 million in 2010, accounting for 3.5 million deaths,
to 439 million in 2030 [3,10,11]. Up to 80% of patients
with DM live in low income and developing countries
[12]. Asia is the epicenter of the growing burden of
DM [10] and the largest contribution is from India
and China [13].
In one nationally representative report from Iran, the
prevalence of DM among adults, 25-64 years old, was
7.7% (around 2 million), among whom one half were un-
aware of their disease. Additionally, 16.8% or 4.4 million
of Iranian adults were estimated to have impaired fasting
glucose [14].
Worldwide, 70% of diabetics live in TB endemic
countries. In the 22 countries with the highest burden
of TB, the prevalence of DM in the general popula-
tion ranges from 2% to 9% [15], and eight of the ten
countries with the highest incidence of DM are also
classified as high burden countries for TB by the World
Health Organization (WHO) [2]. Indonesia, with the
third highest burden of TB in the world, has the fourth
highest number of diabetics [16]. China, India, Peru and
Russia are other countries that need to be given particular
attention [17].
Notably, pulmonary TB is the ninth most frequent
complication of DM [18] and due to a rising prevalence
of DM, the relative contribution of DM to the TB epi-
demic is increasing [3,10].
Diabetes mellitus as a risk factor for tuberculosis
Latent infection
The pathophysiology of tuberculosis is complex. Acqui-
sition of the infection is primarily dependent on exogen-
ous factors; however, reactivation of disease is largely
under the influence of immune sufficiency [19]. In spite
of frequent studies about the link between DM and ac-
tive tuberculosis, the effect of DM on the frequency of
latent TB has been less investigated. The few existing re-
ports about a higher prevalence of latent TB infection
among diabetics have been confounded by an absence of
control groups [20-22]. Results of one study showed the
reaction to purified protein derivate (PPD) is signifi-
cantly correlated to the degree of hyperglycemia [23].
In other studies, the prevalence of TB infection was
not affected by the presence of diabetes [4,24,25], or
its effect was removed after adjusting for other variables
[26]. Therefore, it appears that diabetic patients are not at
greater risk for infection with M. tuberculosis.
Active disease
The frequency of DM among active cases of tuberculosis
was 5.6%, 7.3% and 14.8% in studies from India, Turkey
and Indonesia, respectively. In 35% to 61% of these pa-
tients, DM was diagnosed for the first time after detectionof TB [27-29]. Furthermore, impaired glucose tolerance is
common [30]. Some suggested that reversible glucose in-
tolerance is not specific for tuberculosis and may occur in
the setting of any infection such as pneumonia, [31] but
many studies have confirmed a special correlation be-
tween DM and active TB.
In 10 case control studies, the pooled odds ratio of TB
among DM cases was 2.2 (ranged from 1.16 to 7.81) and
in 4 cohort studies pooled relative risk was 2.52 (95% CI:
1.53 to 4.03) [5,32]. The degree of this effect can be in-
fluenced by factors such as age, DM type, severity of
DM, prevalence of TB in the region, and ethnicity.
The relation between DM and TB is more prominent
in younger people [33]. It seems that patients with type
1 DM are more susceptible than who have type 2 DM.
This higher susceptibility may be related to a longer dur-
ation of disease or could be due to the fact that control
of hyperglycemia is more difficult among type 1 [3,34].
Additionally, the risk of TB is higher among patients
who are using insulin [35], particularly, those who need
higher doses of Insulin [36,37]. Poor glycemic control
has been significantly associated with the occurrence of
TB [38]. In one study, there was a correlation between
active TB and the level of glycosylated hemoglobin
(HbA1c) (hazard ratio 1.39, 95% CI: 1.18-1.63 per unit
increase) [4].
In populations with a higher incidence of TB, DM is a
more important risk factor [33]. DM accounts for a small
proportion of TB cases in settings such as Australia with a
low incidence of TB [35]. This number was 14.8% in India
and 25% in a Mexican setting [39]. Therefore, population
attributed risk for TB from DM is dependent upon DM
prevalence.
Some authors have suggested that ethnicity may influ-
ence the effect of DM on TB. Influence is greater among
Hispanic and non-north American populations [19,33].
Overall, the risk of tuberculosis attributed to diabetes
is 25% [27]. At an individual level, Acquired immunodefi-
ciency syndrome (AIDS) is a more potent risk factor for
TB in comparison to DM, but due to the high frequency
of DM, its effect on the TB burden is equal or even greater
than AIDS. In communities with a high burden of HIV in-
fection, the effect of DM may be masked by HIV [2].
Some have suggested that a higher frequency of TB
among patients with DM may be related to more fre-
quent contact with health care settings and that trans-
mission of disease is more probable in these settings.
Adjustment for contact history as a possible confound-
ing factor, however, did not reduce the strength of the
association [40].
Both forms of active TB, primary and reactivated, are
equally frequent among DM patients [27,41].
In summary, data from case control and cohort studies
have shown that DM is a risk factor for active TB regardless
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place of study [33].
Effect of diabetes on clinical characteristics of
tuberculosis
Diabetic TB patients are usually older than those with-
out DM. This may be due to an association of type 2
DM with older age. Some have reported no difference in
term of gender but some reported higher frequency
among men [3,42].
Some symptoms of DM and TB are similar: weight loss
and fatigue are common to both [43]. Compared to non-
DM patients, TB patients with DM usually have a higher
body weight, [3] although some have reported weight loss
as being more common among DM cases [28].
A few studies have shown that the clinical characteris-
tics of TB do not differ among diabetic and non-diabetic
patients [3,29,41,42,44-46]. In one study, diabetic TB
patients had more symptoms but did not have a more
severe form of TB [28].
Extra-pulmonary involvement has been reported to be
less common among diabetic TB patients than in non-
diabetics [3].
Webb and colleagues showed a higher mean HbA1c
among TB-DM in comparison to DM without TB [4], but
other studies have shown no difference in the HbA1c
among diabetics with and without TB [28,44].
With regards to the rate of positive smears at the time
of diagnosis, results are conflicting. Although some au-
thors reported a higher frequency of negative sputum
smears among TB DM cases [28], others found DM as
an independent risk factor for numerous acid fast bacilli
on the sputum smear examination [29,42] and some
showed no association between DM and patients’ bac-
teriology results [47]. Conflicting results might be due to
the control status of DM [48].
Effect of diabetes on radiologic manifestations of
tuberculosis
There have been conflicting findings regarding the effect
of DM on the radiologic characteristics of pulmonary tu-
berculosis [3,12]. Concerning the distribution of pulmon-
ary involvement, some studies did not find any difference
between DM and non DM cases [28,44,49-51]. However,
there were other studies that showed a higher incidence of
lower lobe involvement among DM TB cases [52-54].
Also, there was no significant difference in the frequency
of pleural effusions or isolated pleural TB between pa-
tients with and without DM [44,50].
Although some reported the opposite [28,46,49,51,55,56],
it seems that cavitary lesions are more common among dia-
betic patients [29,41,44,53,57,58], especially cavitary nodular
lesions [44]. Some have suggested this difference may
be apparent among uncontrolled DM cases (HbA1c ≥ 7)[48,59]. Another factor related to the frequency of cavitary
lesions was insulin dependency [47]. Furthermore, one
study showed an association between lower lung field in-
volvement and female gender or age greater than 40 years
[47]. Also, it has been suggested that severe pulmonary in-
volvement in DM patients may actually be related to
smoking status and not DM alone [50].
Results of one study of pulmonary TB CT findings
showed a high prevalence of non segmental distribution
(30%) and multiple small cavities among diabetic pa-
tients. However, unusual localization such as lower lobe
lesions, involvement of the anterior segment of the
upper lobes or right middle lobe, was similar between
DM and non DM cases [60].
Of note, differences in patient selection and the defin-
ition of DM have to be considered when it comes to some
of these discrepancies between different studies [3].
Effect of diabetes on treatment response of tuberculosis
Drug reactions
Diabetes can lead to impaired renal function and an in-
creased risk of drug toxicities. Also, DM is reported as a
predictor of drug induced liver injury (DILI) [61]. Hepatic
toxicity due to anti tuberculosis drugs may be increased
[10,32] although we didn’t find any relation between DM
and DILI in our setting [62].
Sputum conversion
Current literature on the effect of DM on sputum bac-
teriological conversion is very conflicting. Some studies
did not show DM to be an independent risk factor asso-
ciated with increased time to sputum conversion [42] or
any relation between DM and sputum conversion rate at
the end of 2nd month [12,28,42,63,64]. On the other
hand, there are studies that showed a trend toward in-
creased time to sputum conversion [1,12,63,65]. In
one study, uncontrolled DM (HbA1c ≥ 7) was a signifi-
cant risk factor for positive sputum culture after two
months [48].
Outcome of TB treatment
Some studies did not show any relation between DM
and the outcome of TB treatment [41,42,44,48,63]. How-
ever, DM may have a negative impact on the outcome of
TB treatment: higher failure rates [1,41,66,67], higher
rates of all-cause mortality [68-70], and death specifically
related to TB [71]. In one study, after adjusting for other
factors, the chance of death was over six times higher in
patients with diabetes [63]. Another study showed an
adjusted odds ratio of 7.65 for treatment failure among
DM in comparison to non DM tuberculosis patients
after removing the effect of covariants such as non-
compliance and drug resistance [28]. Definitive causes of
death were not reported in most of these studies, therefore,
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patients were responsible, or perhaps it was other comor-
bidities attributable to DM [12].
Some explanations for worse outcome are higher rates
of drug resistance, impaired cellular immunity, delay in
sputum conversion, and lower plasma levels of anti TB
drugs; the last may be explained by increased weight of
DM patients or excess weight gain during TB treatment
without an accurate adjustment of drug dosing in the
later phase of treatment [3,72].
Reports have been varied with regards to the effect of
DM on the relapse rate of TB. Some have reported a
higher incidence of relapse in diabetics [66,67] and others
reported no difference [42,64,73]. Also, there is no evi-
dence that DM increases the risk of relapse caused by drug
resistant strains [32].
In conclusion, studies examining the effect of DM on
treatment outcome are difficult to compare, and few of
them have used bacteriological endpoints [3]. Currently,
there is not sufficient evidence to recommend alternative
anti tuberculosis regimen for diabetics. Consequently,
treatment of TB is similar between diabetics and non-
diabetics [32].
Anti tuberculosis plasma concentration
Patients who have DM may have lower plasma concen-
trations of anti TB drugs, particularly rifampin [65,74].
In one study, the mean exposure (AUC0-6h) to rifampin
was 53% lower in TB DM patients than age and sex
matched TB patients without DM in the continuous
phase. This effect was associated with the severity of
hyperglycemia. Additionally, maximum concentration
(Cmax) of rifampin was lower among diabetics. No differ-
ence was found between the time necessary for the drug
to reach the maximum concentration (Tmax) [75]. Sur-
prisingly, there were no differences in the pharmacokin-
etics of rifampin, pyrazinamide, and ethambutol in the
intensive phase [54]. The exact mechanism of lower
plasma drug level is not defined. A decrease in gastric
hydrochloric acid secretion [74] and impaired drug ab-
sorption, even in the absence of clinical gastroparesis
may be the reasons [49]. One study showed no effect on
drug levels [76].
Drug resistance to anti tuberculosis drugs
Multi Drug Resistant (MDR) tuberculosis (concomitant
resistant to isoniazid and rifampin) is an increasing chal-
lenge against the control of TB throughout the world.
Some studies reported no relationship between DM and
MDR TB [42,48,58,77,78]. On the other hand, many au-
thors have found an increased risk of MDR TB among
diabetics [1,73], ranging from 2.1 to 8.8 times more
common [49,79,80]. Also, in one study diabetic patients
frequently relapsed with resistant strains [64].There is no proven explanation about the impact of
DM on drug resistancy in tuberculosis. One mentioned
hypothesis is related to the katG gene that is involved in
the protection of the mycobacterium against oxidative
damage and also encodes an enzyme which transforms
isoniazid to the active form. In type 2 diabetics, produc-
tion of reactive oxygen species may be impaired, so strains
with katG mutations may be better able to survive [81].
Effect of tuberculosis on diabetes mellitus
Glucose intolerance has been reported among 16.5% to
49% of patients with active TB. In one study, 56.6% of
cases with glucose intolerance at the time of diagnosis
had normal glucose levels after treatment of the TB, a
phenomena called “transient hyperglycemia” [59,82].
Additionally, it must be noted that control of hypergly-
cemia is more difficult during the active phase of tuber-
culosis and many patients require insulin for control of
hyperglycemia [83].
Although a definite cause of hyperglycemia associated
with TB had not been identified, some probable mecha-
nisms have been suggested [39]. Inflammation caused by
cytokines such as IL6 and TNFα in response to TB in-
fection may cause an increase in insulin resistance and
decreased insulin production, thereby leading to hyper-
glycemia [84].
Additionally, Isoniazid and rifampin have hypergly-
cemic effects. Also pyrazinamide may result in difficult
control of DM [39,83,85-87]. Rifampin induces metabol-
ism and decreases blood level of sulfonylureas, leading
to hyperglycemia [3]. The maximum effect of this is seen
about one week after starting and disappears two weeks
after discontinuing rifampin [88]. Rifampin doesn’t affect
the metabolism of metformin or insulin [3].
Tuberculosis screening among diabetics
Some believe that similar to other populations suscep-
tible to TB, (i.e. HIV-infected individuals, gold miners,
and prisoners in developing countries) screening for ac-
tive TB among diabetics could improve case detection
and could consequently lead to earlier therapy and pre-
vent transmission of disease [36].
The number of diabetics needed to screen to find one
extra case of TB is directly related to the local TB preva-
lence. For example, in settings with a TB prevalence less
than 25 per 100,000 persons, at least 1,000 diabetic per-
sons have to be screened to find one extra case of TB.
When the prevalence is greater, the number needed to
screen to find one additional case of TB ranges from 4 to
442. Therefore, the yield of screening increases with the
prevalence of TB in the region [36]. Surveillance is crucial
in deciding which form of planning is suitable in settings
with medium to high TB burden with an estimated TB
prevalence exceeding 100 in 100,000 population [32].
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fined. One possible strategy consists of performing chest
X-rays at the time of DM diagnosis, and at regular inter-
vals thereafter However, less specific methods such as
imaging may lead to over diagnosis [10,36].
It is sensible that any diabetic patient with suspicious
symptoms such as cough for more than 2-3 weeks,
weight loss, fever, or an abnormal imaging study should
be investigated for presence of active TB. Screening is
recommended, especially in uncontrolled diabetics and
diabetic children with recent TB exposure. There is cur-
rently insufficient evidence for more active screening
measure [4,5,32].
Prophylaxis for tuberculosis among diabetics
The American Thoracic Society has recommended
performing tuberculin skin test (TST) with purified pro-
tein derivative (PPD) for all diabetic patients. If the indur-
ation is 10 mm or more, prophylactic treatment with
isoniazid is recommended for 6 to 12 months, unless the
patient has had a history of tuberculosis [89]. Some au-
thors have questioned the actual benefit of this recom-
mendation [90]. Of note, the prevalence of M. tuberculosis
infection among diabetics is high and the sensitivity of
TST may be reduced [4].
Only two studies have investigated the advantage of TB
prophylaxis among diabetics. The first was conducted in
Germany in the 1950s where post treatment prophylaxis
with isoniazid for 6-24 months after completion of a full
course of treatment for active TB had been evaluated in
diabetic patients. Recurrence rates were lower in the inter-
vention group [91]. In a second study conducted in Russia
in the 1960s, administration of an analogue of isoniazid
for diabetics lowered the incidence of TB compared to
controls by 2 to 3 times [92]. Both studies were problem-
atic due to the absence of randomization and the lack of
details regarding the interventions [10]. Therefore, the
true effectiveness of chemoprophylaxis in diabetic patients
has remained unknown and only through a randomized
controlled trial can it be properly addressed. However,
conducting of such studies is expensive. Furthermore, the
experience with regards to people living with HIV have
showed poor patient compliance, despite proven efficacy.
Therefore, this research is not high priority because it is
unlikely to change current policy and practice [5,93].
In brief, there is not sufficient evidence to support any
preventive therapy for diabetics with latent TB infection.
However, preventive therapy may be considered for cer-
tain high risk groups such as diabetics who have a close
TB contact [5,32].
Screening for diabetes among patients with tuberculosis
A wide range of DM prevalence from 1.9% to 35% was
reported by screening for DM among patients with TB.The highest values were reported from regions with high
prevalence of DM. Many of these patients were newly
diagnosed as a result of receiving expanded medical at-
tention related to TB treatment [12,27,36,45,59].
In particular, type 2 DM is often unrecognized. In two
studies from Tanzania and Indonesia, 73% and 61% of
diabetics, respectively, were newly diagnosed concurrent
with active TB [3,28,30]. Screening for DM in patients
with TB could improve case detection, early treatment,
and prevention of DM complications [36]. Older age,
obesity, inactive lifestyle, and family history of DM are
risk factors for DM among TB patients [28,45].
The preferred method for screening of DM among TB
cases has not been determined. Measurement of fasting
blood glucose (FBG), random blood glucose (RBG) and
2 hour postprandial glucose (2hPG), urine glucose, HbA1c,
and performance of glucose tolerance test (GTT) have
been suggested [5,10,27,40]. In one study, questions about
symptoms of hyperglycemia led to the diagnosis in all of
the DM cases [45].
Some authors recommend measurement of 2hPG as
the best method. It is easy, cheap, rapid, and reliable.
This method is regularly more sensitive than FBG and
RBG [32]. In Asian populations, the sensitivity of 2hPG
is reportedly higher than FBS and HbA1c [13].
The World Health Organization (WHO) recommends
HbA1c as a diagnostic test for DM. However, it is ex-
pensive and use of this test alone is still controversial.
Urine testing for glucose is insensitive and suboptimal,
especially in the early stages of DM [10].
The best time for screening is not yet clear. Some rec-
ommend screening for DM later in the disease process,
when TB treatment has shown its effect. The reason for
this is that, as an infectious disease, TB may transiently
elevate blood glucose and an infection related hypergly-
cemia may result in misclassification as DM [12,36]. On
the other hand, early screening for DM has some bene-
fits including initiation of diabetes treatment, education
of patients and correction of hyperglycemia, which po-
tentially could have positive effects on the outcome of
TB treatment. Additionally, national TB programs in
many countries refer TB patients to peripheral facilities
where laboratory investigations are difficult to perform.
Therefore, screening for diabetes is recommended at the
start of TB treatment [32,93]. As hyperglycemia may
regress after treatment of TB, verification of glucose
intolerance after cure of TB is necessary. Even after
the return of blood sugar to normal level, subsequent
monitoring is necessary, because it has been shown
that a history of impaired fasting glucose is a strong
predictor of subsequent diabetes [45,94]. Due to these
reasons, some recommend screening both at the time
of diagnosis of TB and three months later after initi-
ating treatment [5].
Baghaei et al. Journal of Diabetes & Metabolic Disorders 2013, 12:58 Page 6 of 8
http://www.jdmdonline.com/content/12/1/58The number of TB patients needed to screen for de-
tection of one extra case of DM ranged from 4 to 54 in
several studies [36]. As a result, screening of DM among
TB cases is more cost-effective than screening of TB
among DM cases.
Unresolved issues
Many critical questions remained unanswered. Well de-
signed studies are necessary to determine the optimal
time and method of screening for DM in TB patients.
Also, the best screening algorithm for diagnosis of TB
among diabetics is unknown. The role of newer tools for
detection of M. tuberculosis infection, such as commer-
cial IFN-γ release assays has not yet been determined.
Larger studies with more definite endpoints are needed
to evaluate the effect of DM on the outcome of TB treat-
ment. The effectiveness of TB preventive therapy may
only be answered through a randomized controlled trial.
Conclusion
The burden of diabetes mellitus is increasing worldwide.
The association between diabetes and tuberculosis is the
next challenge for global tuberculosis control. Improved
understanding of the bidirectional relationship of the
two diseases is necessary for proper planning and collab-
oration to reduce the dual burden of diabetes and TB. In
people with TB, it may be appropriate to actively screen
for DM. Prevention, screening, and treatment of both dis-
eases together is more effective. Perhaps, a model similar
to the TB-HIV program may be the best approach.
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